Anuradhaa Subramanian

Anuradhaa Subramanian

Auto-generated profile, based on publicly available information

Anuradhaa Subramanian

Institute of Applied Health Research, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
APAlessandro Prete
Alessandro Prete
ASAnuradhaa Subramanian
Anuradhaa Subramanian
IBIrina Bancos
Irina Bancos
VCVasileios Chortis
Vasileios Chortis
STStylianos Tsagarakis
Stylianos Tsagarakis
EIENSAT EURINE-ACT Investigators*
ENSAT EURINE-ACT Investigators*
Benign adrenal tumors are commonly discovered on cross-sectional imaging that is done for other reasons. This study examined whether the mild autonomous cortisol secretion often found with these tu... Visual Cardiometabolic Disease Burden in Benign Adrenal Tumors. Benign adrenal tumors are commonly discovered on cross-sectional imaging that is done for other reasons. This study examined... Background: Benign adrenal tumors are commonly discovered on cross-sectional imaging. Mild autonomous cortisol secretion (MACS) is regularly diagnosed, but its effect on cardiometabolic disease in ...

1 September 2019 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
NANicola J. Adderley
Nicola J. Adderley
ASAnuradhaa Subramanian
Anuradhaa Subramanian
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
AYAndreas Yiangou
Andreas Yiangou
KGKrishna Margadhamane Gokhale
Krishna Margadhamane Gokhale
ASAlexandra J. Sinclair
Alexandra J. Sinclair
Idiopathic intracranial hypertension (IIH) is a condition of unknown origin characterized by elevated intracranial pressure typically manifesting as papilledema, with a consequent risk of visual loss and chronic disabling headache.1,2 Incidence and economic burden of IIH are rising in line with global obesity figures.3 Diagnostic criteria include brain imaging to exclude mass lesion, hydrocephalus, and venous thrombosis as well as the presence of papilledema and a lumbar puncture pressure greater than 25 cm cerebrospinal fluid with normal constituents.4 Currently, management focuses on preserving vision and reducing headache morbidity.5

12 March 2019 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
ASAnuradhaa Subramanian
Anuradhaa Subramanian
NANicola J. Adderley
Nicola J. Adderley
ATAlexander Tracy
Alexander Tracy
TTTom Taverner
Tom Taverner
WHWasim Hanif
Wasim Hanif
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
OBJECTIVE This study compared the incidence of obstructive sleep apnea (OSA) in patients with and without type 2 diabetes and investigated risk factors for OSA in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS A retrospective cohort study was performed to compare OSA incidence between adult patients with and without type 2 diabetes matched for age, sex, and BMI. Patients with a prevalent OSA diagnosis were excluded. The study cohort was derived from The Health Improvement Network (THIN), a U.K. primary care database, from 1 January 2005 to 31 December 2017. RESULTS There were 3,110 (0.88%) and 5,968 (0.46%) incident OSA cases identified in the 360,250 exposed and 1,296,489 unexposed patient cohorts, respectively. Adjusted incidence rate ratio (aIRR) of OSA in patients with type 2 diabetes compared with those without was 1.48 (95% CI 1.42–1.55; P < 0.001). In a multivariate regression analysis of patients with type 2 diabetes, significant predictors of OSA were diabetes-related foot disease (1.23 [1.06–1.42]; P = 0.005), being prescribed insulin in the last 60 days (1.58 [1.42–1.75]; P < 0.001), male sex (2.27 [2.09–2.46]; P < 0.001), being overweight (2.02 [1.54–2.64]; P < 0.001) or obese (8.29 [6.42–10.69]; P < 0.001), heart failure (1.41 [1.18–1.70]; P < 0.001), ischemic heart disease (1.22 [1.11–1.34]; P < 0.001), atrial fibrillation (1.23 [1.04–1.46]; P = 0.015), hypertension (1.32 [1.23–1.43]; P < 0.001), and depression (1.75 [1.61–1.91]; P < 0.001). CONCLUSIONS When considered alongside previous evidence, this study indicates that the association between type 2 diabetes and OSA is bidirectional. In addition to known predictors of OSA, diabetes-related foot disease and insulin treatment were identified as risk factors in patients with type 2 diabetes.

21 May 2018 in Obesity Reviews
Verified
Journal Article
Closed access
PDF file
JWJingya Wang
Jingya Wang
DMD. Moore
D. Moore
ASA. Subramanian
A. Subramanian
KCK. K. Cheng
K. K. Cheng
KTK. A. Toulis
K. A. Toulis
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar

1 May 2021 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ASAnuradhaa Subramanian
Anuradhaa Subramanian
AAAstha Anand
Astha Anand
NANicola J Adderley
Nicola J Adderley
KOKelvin Okoth
Kelvin Okoth
KTKonstantinos A Toulis
Konstantinos A Toulis
KNKrishnarajah Nirantharakumar
Krishnarajah Nirantharakumar
Objective: Several recent observational studies have linked metabolic comorbidities to an increased risk from COVID-19. Here we investigated whether women with PCOS are at an increased risk of COVID-19 infection. Design: Population-based closed cohort study between 31 January 2020 and 22 July 2020 in the setting of a UK primary care database (The Health Improvement Network, THIN). Methods: The main outcome was the incidence of COVID-19 coded as suspected or confirmed by the primary care provider. We used Cox proportional hazards regression model with stepwise inclusion of explanatory variables (age, BMI, impaired glucose regulation, androgen excess, anovulation, vitamin D deficiency, hypertension, and cardiovascular disease) to provide unadjusted and adjusted hazard risks (HR) of COVID-19 infection among women with PCOS compared to women without PCOS. Results: We identified 21 292 women with a coded diagnosis of PCO/PCOS and randomly selected 78 310 aged and general practice matched control women. The crude COVID-19 incidence was 18.1 and 11.9 per 1000 person-years among women with and without PCOS, respectively. Age-adjusted Cox regression analysis suggested a 51% higher risk of COVID-19 among women with PCOS compared to women without PCOS (HR: 1.51 (95% CI: 1.27–1.80), P < 0.001). After adjusting for age and BMI, HR reduced to 1.36 (1.14–1.63)], P = 0.001. In the fully adjusted model, women with PCOS had a 28% increased risk of COVID-19 (aHR: 1.28 (1.05–1.56), P = 0.015). Conclusion: Women with PCOS are at an increased risk of COVID-19 infection and should be specifically encouraged to adhere to infection control measures during the COVID-19 pandemic. Significance statement: Women with polycystic ovary syndrome (PCOS) have an increased risk of cardio-metabolic disease, which have been identified as a risk factor for COVID-19. To investigate whether the increased metabolic risk in PCOS translates into an increased risk of COVID-19 infection, we carried out a population-based closed cohort study in the UK during its first wave of the SARS-CoV-2 pandemic (January to July 2020), including 21 292 women with PCOS and 78 310 controls matched for sex, age and general practice location. Results revealed a 52% increased risk of COVID-19 infection in women with PCOS, which remained increased at 28% above controls after adjustment for age, BMI, impaired glucose regulation and other explanatory variables.

20 July 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
OAOlalekan Lee Aiyegbusi
Olalekan Lee Aiyegbusi
CMChristel McMullan
Christel McMullan
SHSarah E Hughes
Sarah E Hughes
GTGrace M. Turner
Grace M. Turner
ASAnuradhaa Subramanian
Anuradhaa Subramanian
DWDavid C. Wraith
David C. Wraith